Meyka Pro banner
Vir Biotechnology, Inc.

Vir Biotechnology, Inc. (NASDAQ: VIR) Stock Competitors & Peer Comparison

See VIR's competitors and their performance on the NASDAQ and across the wider stock market.

VIR●NASDAQ
HealthcareBiotechnology
$9.16
$0.80(8.03%)
U.S. Market is Open · 10:31

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for VIR and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
VIR$9.16-8.03%1.6B-5.15-$1.86N/A
VRTX$530.50-1.50%136.4B28.26$19.03N/A
REGN$955.68+0.02%98.5B20.87$45.63+0.39%
MRNA$207.31-7.19%87.1B-26.41-$8.15N/A
VRNA$106.91+0.11%72.7B-102.80-$1.04N/A
ARGX$937.22-2.38%59.8B34.29$27.73N/A
ONC$409.03-1.80%43.9B72.41$5.68N/A
SGEN$228.74-0.07%43.2B-57.19-$4.00N/A
RVMD$162.60-5.62%36.1B-18.92-$8.82N/A
RVMDW$6.65-18.40%34.1B-0.80-$8.82N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

VIR vs VRTX Comparison November 2026

Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VIR stands at 1.6B. In comparison, VRTX has a market cap of 136.4B. Regarding current trading prices, VIR is priced at $9.16 on the NASDAQ, while VRTX trades at $530.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VIR currently has a P/E ratio of -5.15, whereas VRTX's P/E ratio is 28.26. In terms of profitability, VIR's ROE is -0.21%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, VIR is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check VRTX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions